 |
PRESS
RELEASE
BurnsAdler
Partners with Sigma-Tau S.p.A.
to Promote Natulan®
Charlotte, North Carolina (February 18, 2005)
- BurnsAdler Pharmaceuticals, Inc. announced today that they
have partnered with Sigma-Tau S.p.A. for the promotion and
distribution of Natulan® (procarbazine) in Latin America and
the Caribbean. Natulan® is indicated for use in combination
with other anticancer drugs for the treatment of Stage III
and IV Hodgkin's disease as part of the MOPP (nitrogen mustard,
vincristine, procarbazine, prednisone) treatment regimen.
Natulan® was marketed globally by Roche before being acquired
by Sigma-Tau.
Banks
Bourne, President of BurnsAdler remarked, "Natulan® is well
known by hematologists and oncologists throughout the world.
We look forward to bringing back this life saving medication
to patients throughout Latin America and the Caribbean."
Procarbazine was discovered in the late 1950's during a search
for monoamine oxidase (MAO) inhibitors with less serious side
effects. As early as 1962, clinical trials were reported describing
procarbazine's effectiveness in Hodgkin's disease. Procarbazine
is a unique antineoplastic agent with multiple sites of action.
It inhibits incorporation of small DNA precursors, as well
as RNA and protein synthesis. Procarbazine is not cross-resistant
with other alkylating agents.
Sigma-Tau
is a leading research-based Italian pharmaceutical company
with annual revenues of approximately € 620 million and over
2400 employees worldwide. Therapeutic areas in which the company's
research and development are focused include: oncology, neurology,
cardiovascular, gastroenterology, metabolism and immunology.
Sigma-Tau has operating subsidiaries throughout Europe and
the U.S. and maintains a presence in all of the world's major
pharmaceutical markets.
BurnsAdler
is a specialty pharmaceutical company that in-licenses and
promotes products in Europe, South America, Mexico, Canada,
Puerto Rico and the Caribbean. BurnsAdler's portfolio currently
includes products in the following fields: cardiovascular,
orthopaedic, oncology and epilepsy.
For
additional information about this news release contact Bryan
Somerville at +1.704.552.8410 Ext. 223. For additional information
about BurnsAdler, please refer to the company's website at
www.burnsadler.com.
|
BurnsAdler provides cost effective international product distribution and promotion for select emerging pharmaceutical companies.
 Print this page.
|
